Is Liraglutide Safe While Trying to Conceive?

What Liraglutide Is and Why Women Use It

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist given by daily subcutaneous injection. It mimics GLP-1, a gut hormone that slows gastric emptying, suppresses appetite, and stimulates glucose-dependent insulin secretion. The FDA approved it in 2010 as Victoza for type 2 diabetes (1.2 mg or 1.8 mg daily) and in 2014 as Saxenda for chronic weight management (titrated to 3 mg daily).

For women specifically, liraglutide touches several conditions that sit at the intersection of hormones and metabolism.

PCOS, Fertility, and the Weight Connection

Polycystic ovary syndrome (PCOS) affects roughly 8 to 13 percent of women of reproductive age worldwide. Insulin resistance and excess weight drive much of the reproductive dysfunction in PCOS: anovulation, irregular cycles, and elevated androgens. Because liraglutide improves insulin sensitivity and promotes weight loss, clinicians sometimes prescribe it off-label or as an adjunct in women with PCOS who have not responded to metformin.

A 2019 trial published in Fertility and Sterility found that liraglutide 1.8 mg daily added to metformin improved menstrual regularity and ovulation rates in women with PCOS compared to metformin alone. That is clinically meaningful, but it also means that a woman starting liraglutide for PCOS may begin ovulating more predictably and could become pregnant while still on the drug if she is not using contraception.

Obesity Medicine and Weight Loss Before Pregnancy

Women with obesity who are planning a pregnancy face elevated risks of gestational diabetes, preeclampsia, cesarean delivery, and fetal macrosomia. Losing weight before conception reduces those risks. Liraglutide (Saxenda) produces a mean body weight loss of approximately 5 to 8 percent over 56 weeks in clinical trials, making it a reasonable pre-conception weight loss tool in principle. The timing problem is that the drug must be stopped well before conception, not continued through early pregnancy.

Thyroid Disease and Postpartum Thyroiditis

Women with type 2 diabetes and hypothyroidism sometimes ask whether liraglutide is appropriate. The FDA label for both Victoza and Saxenda carries a boxed warning for thyroid C-cell tumors based on rodent data. Whether this translates to humans is not established, but women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use liraglutide at any life stage.

What the Animal Data Actually Show

Before any human pregnancy data is discussed, it is worth being precise about what the animal studies found, because this is the primary basis for the pregnancy guidance.

Rat and Rabbit Studies

The FDA labels for both Victoza and Saxenda summarize the reproductive toxicology data. In pregnant rats given liraglutide throughout organogenesis, fetal harm including skeletal abnormalities, reduced fetal weight, and increased early pregnancy loss occurred at exposures approximately 0.8 times the maximum recommended human dose of 1.8 mg/day. In rabbits, early pregnancy loss and fetal abnormalities were seen at exposures well below those producing maternal toxicity.

These are not high-dose, clearly supratherapeutic exposures. The harm occurred at doses close to what a woman taking the medication would experience. That fact is the scientific reason for the "discontinue before conception" recommendation.

What the Animal Data Cannot Tell You

Animal-to-human extrapolation in reproductive toxicology is imperfect. GLP-1 receptors are present in rodent placentas and fetal tissue, but the distribution and functional significance in human placenta is less well characterized. A 2019 review in Endocrinology confirmed GLP-1 receptor expression in human trophoblast cells, raising plausible concern that circulating liraglutide could affect placental development, though direct evidence of this mechanism causing harm in humans has not been published.

The honest summary: animal data raise a genuine signal at clinically relevant doses, and the absence of human pregnancy trial data means that signal cannot be dismissed.

Human Pregnancy Data: What Exists (and What Doesn't)

No randomized controlled trial of liraglutide in pregnant women has been conducted, and none is ethically feasible to design. The human data that exist come from case reports, pharmacovigilance databases, and pregnancy registries.

Pregnancy Registry and Pharmacovigilance Data

Novo Nordisk, the manufacturer of both Victoza and Saxenda, maintained a Victoza pregnancy registry for several years. The registry was small and the outcomes were inconclusive because most exposures were brief and occurred in early pregnancy before the woman knew she was pregnant. No registry has yet accumulated enough cases to provide reliable risk estimates for major congenital malformations or spontaneous abortion attributable to liraglutide.

A 2021 review in Diabetes Care noted that GLP-1 receptor agonists as a drug class lack sufficient human gestational exposure data to define teratogenic risk. This is not reassurance. It is an evidence gap that should be communicated plainly.

Inadvertent First-Trimester Exposure

Because liraglutide may restore ovulation in women with PCOS or insulin resistance, inadvertent first-trimester exposure does occur. If you were taking liraglutide and discovered an unplanned pregnancy, the first step is to stop the medication immediately and contact your prescribing clinician. A maternal-fetal medicine specialist can help you understand the timing of exposure relative to organogenesis (days 17 to 56 post-conception) and whether any additional monitoring is indicated.

The WomanRx clinical team uses a structured three-question framework for any patient who reports inadvertent GLP-1 exposure in early pregnancy:

1. What was the gestational age at last dose, and does that overlap with the organogenesis window?
2. What dose was the patient taking (1.2 mg, 1.8 mg, or up to 3 mg), given that higher doses produce greater systemic exposure?
3. Does the patient have any additional risk factors (prior pregnancy loss, structural uterine pathology, thyroid disease) that warrant earlier anatomy screening?

This framework does not change the recommendation to stop the drug immediately, but it helps triage which patients need early targeted ultrasound at 18 to 20 weeks versus standard anatomy screening.

Pregnancy and Lactation Safety: The Required Conversation

This section is required reading for any woman on liraglutide who is thinking about becoming pregnant, is already pregnant, or is planning to breastfeed.

FDA Labeling and Pregnancy

The FDA label for Saxenda states explicitly: "Discontinue Saxenda when pregnancy is recognized. Based on animal data, liraglutide may cause fetal harm when administered to a pregnant woman." The Victoza label language is similar.

Post-2015 FDA labeling no longer assigns A/B/C/D/X letter categories. Instead, labels describe the actual data and the risk in narrative form. For liraglutide, that narrative centers on the animal findings described above and the absence of adequate human data.

The FDA label recommends stopping liraglutide at least two months before planned pregnancy. This two-month washout is longer than the drug's half-life (approximately 13 hours) would strictly require. The rationale is partly pharmacokinetic conservatism and partly to allow weight stabilization and planning for alternative diabetes or weight management strategies.

Breastfeeding and Liraglutide

The LactMed database, maintained by the National Library of Medicine, states that no information is available on the use of liraglutide during breastfeeding and that the drug is not recommended during lactation. Because liraglutide is a large peptide (molecular weight approximately 3,751 daltons), it is likely to have low oral bioavailability in an infant even if trace amounts transfer into milk, since peptides are digested in the neonatal gut. However, "likely low risk" is not the same as "studied and confirmed safe," and the current guidance conservatively advises against use while breastfeeding.

If you are postpartum and your diabetes or weight management requires pharmacologic support, discuss with your clinician whether metformin (which has LactMed safety data), insulin, or lifestyle measures can bridge the period of lactation.

Contraception While on Liraglutide

Any woman taking liraglutide who does not want to become pregnant should use effective contraception. This is especially relevant for women with PCOS, because liraglutide may restore ovulation in women who previously had irregular or absent cycles and who may not have been using contraception because they believed they were not ovulating. The restoration of fertility is a therapeutic success, but it requires a corresponding contraception conversation.

ACOG recommends discussing contraception proactively with any patient starting a medication known to affect ovulation or fertility. Long-acting reversible contraceptives (LARCs), such as hormonal IUDs or subdermal implants, are appropriate options that do not interact with liraglutide pharmacokinetically.

Note also that liraglutide slows gastric emptying, which may theoretically reduce the peak absorption of oral contraceptive pills taken around the same time as a meal. The clinical significance of this interaction on contraceptive efficacy has not been formally studied. Women relying on oral contraceptives while taking liraglutide should be aware of this theoretical concern, and clinicians may wish to counsel patients to take their oral contraceptive at a consistent time relative to the liraglutide injection and meals.

Who Should Not Take Liraglutide While Trying to Conceive

The short answer: no woman actively trying to conceive should be on liraglutide. The guidance below stratifies the conversation by life stage.

Reproductive Years, Not Currently Trying to Conceive

If you are in your reproductive years, not currently trying to conceive, and are taking liraglutide for weight management or diabetes, continue the medication with effective contraception. Discuss your family planning timeline with your prescribing clinician so you can plan a two-month washout before stopping contraception.

Actively Trying to Conceive

Stop liraglutide. This is not a gray area. The FDA label, the animal data, and the expert consensus all point in the same direction. Work with your clinician on alternative strategies:

• For type 2 diabetes: insulin (the most studied in pregnancy), or metformin if your clinician agrees this is appropriate for your specific situation, though ACOG notes that metformin crosses the placenta and its long-term fetal effects are still being studied.
• For weight management: structured dietary intervention, referral to a registered dietitian with perinatal nutrition expertise, and continued physical activity as appropriate.

Perimenopause and Post-menopause

Women in perimenopause and post-menopause do not face pregnancy risk, so the conception-related contraindication does not apply. Liraglutide remains an option for weight management and metabolic health in these life stages. The thyroid C-cell tumor boxed warning and other contraindications (personal or family history of medullary thyroid carcinoma, MEN 2) apply regardless of age.

Women with PCOS Seeking Fertility Treatment

If you have PCOS and are planning fertility treatment, your reproductive endocrinologist may prescribe liraglutide as a pre-conception metabolic optimization strategy, but it should be stopped at least two months before any insemination or embryo transfer. A 2022 meta-analysis in Fertility and Sterility found that GLP-1 receptor agonists used in the preconception period in women with PCOS improved BMI and insulin sensitivity without evidence of adverse outcomes when discontinued before conception, though the included studies were small and heterogeneous.

What Happens to Weight and Metabolic Health When You Stop

Stopping liraglutide typically results in some weight regain. The SCALE Maintenance trial showed that patients who stopped liraglutide 3 mg after one year of treatment regained approximately two-thirds of the lost weight within the subsequent year. For women planning pregnancy, this is not a reason to keep taking the drug. It is a reason to plan the transition thoughtfully.

Before stopping liraglutide for a planned conception attempt, consider:

• Setting a realistic weight goal during the washout period and working with a dietitian.
• Establishing a physical activity routine that can continue safely into early pregnancy.
• Discussing whether any alternative medications (metformin for PCOS/insulin resistance) are appropriate during the trying-to-conceive window.
• Confirming that blood glucose control is adequate before removing the medication if you have type 2 diabetes.

Weight gain during the washout is not a treatment failure. It is a physiologically expected response that should be managed, not a reason to delay the two-month washout.

The Evidence Gap: What We Still Don't Know

Women have historically been underrepresented in clinical drug trials, and pregnant and lactating women are almost entirely excluded. The liraglutide evidence gap is not unique, but it is significant.

Specific questions that remain unanswered in humans:

• Does first-trimester liraglutide exposure increase the absolute risk of major congenital malformations above the background rate of approximately 2 to 3 percent in the general population?
• Does liraglutide transfer into human breast milk, and if so, at what concentration?
• Does the GLP-1 receptor expression in human trophoblast translate into any clinically meaningful effect on placental development or function?
• Is the two-month washout recommendation based on pharmacokinetic modeling, clinical evidence, or regulatory conservatism? (The answer is primarily regulatory conservatism and the drug's approximately 13-hour half-life, which means the drug is pharmacokinetically cleared within days, but a longer buffer is recommended given the animal data.)

A 2023 statement from the Endocrine Society on GLP-1 receptor agonists and pregnancy called for the establishment of a comprehensive pregnancy registry to generate the human gestational safety data that currently does not exist. Until that registry matures, all guidance is extrapolated primarily from animal studies and mechanistic reasoning.

As a direct quotation from the FDA Saxenda prescribing information: "Based on animal data, liraglutide may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception."

And as the LactMed entry summarizes: "Because of the lack of data on the use of liraglutide during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant."

Talking to Your Clinician: Questions to Bring to Your Next Appointment

If you are on liraglutide and thinking about pregnancy in the next one to two years, bring these specific questions:

1. How far in advance of stopping contraception should I stop liraglutide?
2. What is the plan for my diabetes or weight management during the trying-to-conceive period and pregnancy?
3. Should I be screened for PCOS or anovulation before stopping contraception, given that liraglutide may have been restoring my cycles?
4. If I experience an unplanned pregnancy while still on liraglutide, what do I do immediately, and who do I call?
5. Is a preconception consultation with a maternal-fetal medicine specialist appropriate given my medical history?